Publications by authors named "Eli Eyal"

17Publications

Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects.

Basic Clin Pharmacol Toxicol 2019 Mar 21;124(3):273-284. Epub 2018 Oct 21.

Teva Pharmaceuticals Ltd., Netanya, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcpt.13131DOI Listing
March 2019

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.

Clin Pharmacol Drug Dev 2019 01 22;8(1):49-59. Epub 2018 May 22.

eResearch Technology, Inc, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.442DOI Listing
January 2019

Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.

Drug Alcohol Depend 2016 Sep 28;166:13-20. Epub 2016 May 28.

Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2016.05.019DOI Listing
September 2016

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.

Brain 2016 07 13;139(Pt 7):2050-62. Epub 2016 May 13.

4 Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Canada 5 Institute of Medical Science, University of Toronto, Toronto, Canada 7 Department of Psychiatry, University of Toronto, Toronto, Canada 8 Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada 11 Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada 12 Lancaster Medical School and Data Science Institute, Lancaster University, Lancaster, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/aww109DOI Listing
July 2016

Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.

Int J Neurosci 2016 Oct 18;126(10):942-6. Epub 2016 Mar 18.

c Teva Pharmaceuticals , Petah Tikva , Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/00207454.2016.1154552DOI Listing
October 2016

Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.

J Clin Psychopharmacol 2015 Aug;35(4):396-405

From the *Altreos Research Partners, Inc and †Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; ‡Research and Development, Teva Pharmaceuticals, Netanya, Israel; and §Algorithme Pharma, Laval, Québec; and ∥DL Global Partners Inc and ¶Biopharma Services Inc, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000347DOI Listing
August 2015

Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.

Lancet Neurol 2015 Feb 8;14(2):145-52. Epub 2014 Dec 8.

Clinical Investigation Center CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and University Hospital of Toulouse, Faculty of Medicine, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(14)70288-1DOI Listing
February 2015

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

JAMA Neurol 2015 Jan;72(1):88-95

Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia3Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia4Department of Veterans Affairs, Philadelphia VA Medi.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2014.2472DOI Listing
January 2015

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.

Mov Disord 2014 Jul 11;29(8):1028-34. Epub 2014 Jun 11.

Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25877DOI Listing
July 2014

Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.

Parkinsonism Relat Disord 2014 Jun 5;20(6):640-3. Epub 2014 Mar 5.

Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2014.02.024DOI Listing
June 2014

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

Pharmacogenet Genomics 2007 Aug;17(8):657-66

Division of Neuroimmunology and Multiple Sclerosis Center, Rappaport Faculty of Medicine and Research Institute, Technion and Carmel Medical Center, Haifa, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e3281299169DOI Listing
August 2007